IMS Health Reports U.S. Prescription Sales Grew 1.3 Percent in 2008 to $291 Billion
NORWALK, CT, March 19, 2009 – IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today reported annual U.S. prescription sales growth of 1.3 percent in 2008, to $291 billion. Dispensed prescription volume in the U.S. grew at a 0.9 percent pace.
Factors influencing the market’s slower growth in 2008 included higher demand for less-expensive generic drugs, lower new product sales, and reduced consumer demand due to the economic turndown.
Across the major therapy classes, lipid regulators were the most widely dispensed retail prescription medications on a volume basis in 2008, followed by codeine and combinations, anti-depressants, ACE inhibitors and beta blockers. In terms of overall prescription sales sold through both retail and non-retail channels, antipsychotics led all therapy classes followed by lipid regulators, proton pump inhibitors and seizure disorder medications.
For more information about the U.S. pharmaceutical market and the top therapeutic classes, products and sales distribution channels, go to http://www.imshealth.com/media.
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.3 billion in 2008 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.
Posted: March 2009